서브메뉴
검색
상세정보
The market in mind [electronic resources] : how financialization is shaping neuroscience, translational medicine, and innovation in biotechnology
![The market in mind [electronic resources] : how financialization is shaping neuroscience, ...](/Sponge/Images/bookDefaults/EBbookdefaultsmall.png)
The market in mind [electronic resources] : how financialization is shaping neuroscience, translational medicine, and innovation in biotechnology
상세정보
- 자료유형
- 전자책(국외)
- 미국국회도서관 청구기호
- R850
- 자관 청구기호
- 기본표목-개인명
- 표제와 책임표시사항
- The market in mind [electronic resources] : how financialization is shaping neuroscience, translational medicine, and innovation in biotechnology / Mark D. Robinson.
- 발행, 배포, 간사 사항
- 형태사항
- 1 online resource (312 pages).
- 요약 등 주기
- 요약A critical examination of translational medicine, when private risk is transferred to the public sector and university research teams become tech startups for global investors. A global shift has secretly transformed science and medicine. Starting in 2003, biomedical research in the West has been reshaped by the emergence of translational science and medicine--the idea that the aim of research is to translate findings as quickly as possible into medical products. In The Market in Mind , Mark Dennis Robinson charts this shift, arguing that the new research paradigm has turned university research teams into small biotechnology startups and their industry partners into early-stage investment firms. There is also a larger, surprising consequence from this shift: according to Robinson, translational science and medicine enable biopharmaceutical firms, as part of a broader financial strategy, to outsource the riskiest parts of research to nonprofit universities. Robinson examines the implications of this new configuration. What happens, for example, when universities absorb unknown levels of risk Robinson argues that in the years since the global financial crisis translational science and medicine has brought about "the financialization of health." Robinson explores such topics as shareholder anxiety and industry retreat from Alzheimer's and depression research; how laboratory research is understood as health innovation even when there is no product; the emergence of investor networking events as crucial for viewing science in a market context; and the place of patients in research decisions. Although translational medicine justifies itself by the goal of relieving patients' suffering, Robinson finds patients' voices largely marginalized in translational neuroscience.
- 주제명부출표목-일반주제명
- 주제명부출표목-일반주제명
- 주제명부출표목-일반주제명
- 주제명부출표목-일반주제명
- 기타형태저록
- Print version Robinson Mark D author Market in mind
- 전자적 위치 및 접속
- 링크정보보기
MARC
008220118s2019 us s 00 eng c■001on1082364765
■003OCoLC
■00520190703054119.5
■006m d
■007cr cnu|||unuuu
■020 ▼a9780262352963
■020 ▼a0262352966
■020 ▼z9780262536875
■035 ▼a2180941
■035 ▼a(OCoLC)1082364765
■037 ▼a9780262352963▼bMIT Press
■040 ▼aMITPR▼beng▼erda▼epn▼cMITPR▼dOCLCF▼dOCLCA▼dN$T
■050 4▼aR850
■072 7▼aSCI▼x075000▼2bisacsh
■072 7▼aMED▼x057000▼2bisacsh
■072 7▼aTEC▼x059000▼2bisacsh
■072 7▼aPSAD▼2bicssc
■072 7▼aMJN▼2bicssc
■072 7▼aMQW▼2bicssc
■08204▼a610.72▼223
■090 ▼a전자도서
■1001 ▼aRobinson, Mark Dennis▼eauthor.
■24514▼aThe market in mind▼h[electronic resources] :▼bhow financialization is shaping neuroscience, translational medicine, and innovation in biotechnology /▼cMark D. Robinson.
■260 ▼aCambridge▼bMIT Press▼c2019.
■300 ▼a1 online resource (312 pages).
■520 ▼aA critical examination of translational medicine, when private risk is transferred to the public sector and university research teams become tech startups for global investors. A global shift has secretly transformed science and medicine. Starting in 2003, biomedical research in the West has been reshaped by the emergence of translational science and medicine--the idea that the aim of research is to translate findings as quickly as possible into medical products. In The Market in Mind , Mark Dennis Robinson charts this shift, arguing that the new research paradigm has turned university research teams into small biotechnology startups and their industry partners into early-stage investment firms. There is also a larger, surprising consequence from this shift: according to Robinson, translational science and medicine enable biopharmaceutical firms, as part of a broader financial strategy, to outsource the riskiest parts of research to nonprofit universities. Robinson examines the implications of this new configuration. What happens, for example, when universities absorb unknown levels of risk Robinson argues that in the years since the global financial crisis translational science and medicine has brought about "the financialization of health." Robinson explores such topics as shareholder anxiety and industry retreat from Alzheimer's and depression research; how laboratory research is understood as health innovation even when there is no product; the emergence of investor networking events as crucial for viewing science in a market context; and the place of patients in research decisions. Although translational medicine justifies itself by the goal of relieving patients' suffering, Robinson finds patients' voices largely marginalized in translational neuroscience.
■650 0▼aMedical economics.
■650 0▼aMedicine▼xResearch.
■650 7▼aMedical economics.▼2fast▼0(OCoLC)fst01014004
■650 7▼aMedicine▼xResearch.▼2fast▼0(OCoLC)fst01015059
■655 4▼aElectronic books.
■77608▼iPrint version▼aRobinson, Mark D., author.▼tMarket in mind▼z9780262536875▼w(DLC) 2018039817▼w(OCoLC)1049742734
■85640▼3EBSCOhost▼uhttps://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=2180941
한글
ENG
日本
中文
Việt Nam